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Background: Antibiotic and oral corticosteroid prescribing rate in patients suffering from acute exacerbations of
chronic obstructive pulmonary disease (COPD) or asthma in general practice are only sparsely described. Our aim
was to identify predictors for such prescribing when results from CRP testing, spirometry, and pulse oximetry are
available.
Methods: Patients aged 40 years or more diagnosed with asthma, COPD or both, the previous five years from
seven general practice offices in Norway, were invited to a baseline examination and asked to visit their GPs during
exacerbations the following 12 months. At all visits, symptoms, chest findings, and results from spirometry, pulse
oximetry and CRP testing were registered.
Results: Out of the 376 who took part in baseline examination, 95 patients with an exacerbation were included in
the analysis. Based on the diagnosis made by GPs, 46 patients (48.4%) were only registered with asthma, and 49
(51.6%) with COPD (or both diagnosis). 11 patients had taken antibiotics and 16 had taken systemic corticosteroids
prior to their visit to their GPs. After excluding those already treated, antibiotics were prescribed in 34.9% and
systemic corticosteroids in 42.5% of patients diagnosed with COPD compared to 14.6% and 30.8% respectively in
patients only diagnosed with asthma (P = 0.02, P = 0.2). In the COPD group, antibiotic prescribing was not
significantly associated with purulence or other respiratory symptoms, but increased phlegm was a significant
predictor of antibiotic prescribing in the whole sample (P = 0.04). Prolonged expiration, wheezes and diminished
breath sounds also predicted the prescribing of both antibiotics and systemic corticosteroids in the whole sample
with P values < 0.01. The prescribing rate of antibiotics and systemic corticosteroids also increased with increasing
CRP value (P = 0.001 and P = 0.01, respectively) and with decreasing oxygen saturation (P = 0.01 and P = 0.003,
respectively). FEV1/FVC < 0.7 at baseline was as significant predictor in patients with COPD and in the whole sample
of patients regarding treatment with antibiotics (P = 0.004 and P = 0.001, respectively) and treatment with systemic
corticosteroids (P = 0.004 and P = 0.001, respectively).
Conclusion: Chest findings, raised CRP value and decreased oxygen saturation were stronger predictors of
prescribing of antibiotics and systemic corticosteroids than were respiratory symptoms. Further evaluation of the
importance of these findings to guide treatment of asthma and COPD exacerbations is warranted.
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Chronic obstructive pulmonary disease (COPD) is a
huge health problem and it is expected to become an
even bigger problem due to the rapidly ageing popula-
tion worldwide [1]. The course of COPD is usually
punctuated by episodes of acute worsening of respiratory
symptoms, known as acute exacerbations (AECOPD).
Among persons older than 40 years in Norway, spirom-
etry revealed COPD in 18% [2], most of them have mild
COPD and not more than 4% are registered with a
COPD diagnosis in Norwegian primary care [3]. Patients
with asthma also experience exacerbation of their disease,
which is characterized by a progressive increase in respira-
tory symptoms and progressive decrease in lung function
sufficient to require a change in treatment [4]. The preva-
lence of asthma has increased both for children and adults
in Norway. It is estimated that 8% of all adults have the
disease [5]. In a study on asthma exacerbations, 8.8% of
the patients experienced an exacerbation of their asthma
during a 3 months period [6]. We have previously re-
ported that in Norwegian COPD patients 46.8% experi-
enced one exacerbation or more in one year [7], similar to
the frequency found in an international study [8].
Although both COPD and asthma involves bronchial
inflammation and airway limitation, we know that the
underlying pathophysiology differs [9,10], but in real life,109 patients visited their 
GPs due to an 
exacerbation
96 patients had sufficient 
data registered
95 patients included in 
the analysis
84 patients included in 
the analysis to predict 
antibiotic prescribing
11 patients had been treated 
with antibiotics before the 
consultation 
Figure 1 Flow of patients through our study.it is still difficult to differentiate between these diseases [3]
and a combination of the two diseases may occur [3,11].
Although the trigger for severe exacerbations in pa-
tients with COPD cannot be identified in almost one
third of cases, bacterial infection, viral infection and
environmental pollutants are triggers in the other two
thirds [12] and it is estimated that 50 to 70% of the exac-
erbations of COPD have an infectious etiology [13]. The
standard treatment of AECOPD is usually short-acting
bronchodilators, oral corticosteroids and/or antibiotics
depending on the presenting symptoms. Antibiotic treat-
ment in patients with AECOPD has been a matter of de-
bate in many years mainly due to difficulties in defining
exacerbations and in demonstrating their bacterial eti-
ology. Anthonisen and colleagues divided the exacerba-
tions into three types based on the increase of the three
cardinal symptoms: dyspnea, phlegm and purulence with
type 1 being the most severe (all three symptoms) [14].
Recent work has shown correlation between sputum
purulence and the presence of bacteria [15]. Therefore,
the current guidelines recommend antibiotic therapy to
Anthonisen type 1 patients and to those with two of the
three cardinal symptoms, if increased purulence of phlegm
is one of them [13,14,16].
Exacerbations of asthma usually occur in response to an
external stimulus (viral upper respiratory tract infection orMissing data about the 
exacerbation in 13
patients
One patient was admitted 
to hospital
79 patients included in 
the analysis to predict 
corticosteroid prescribing
16 patients had been treated 
with corticosteroids before 
the consultation







All 46 (48.4) 49 (51.6) 95 (100)
Age 65 years or more 17 (37.0) 28 (57.1) 45 (47.4)
Gender
Male 17 (37.0) 18 (36.7) 35 (36.8)
Female 29 (63.0) 31 (63.3) 60 (63.2)
Smoking status
Never smoker 18 (39.1) 8 (16.3) 26 (27.4)
Current smoker 12 (26.1) 18 (36.7) 30 (31.6)
Ex-smoker 16 (34.8) 23 (46.9) 39 (41.1)
Spirometry at baseline
FEV1/FVC < 0.7 7 (15.2) 32 (65.3) 39 (41.1)
Respiratory symptoms
Dyspnea, bothersome or very
bothersome
42 (91.3) 47 (95.9) 89 (93.7)
very bothersome 12 (26.1) 19 (38.8) 31 (32.6)
Phlegm, bothersome or very
bothersome
35 (76.1) 36 (73.5) 71 (74.7)
very bothersome 9 (19.6) 9 (18.4) 18 (18.9)
Purulence 23 (50.0) 21 (42.9) 44 (46.3)
Coughing, bothersome or very
bothersome
42 (91.3) 43 (87.8) 85 (89.5)
very bothersome 16 (34.8) 15 (30.6) 31 (32.6)
Chest findings
Prolonged expiration 16 (34.8) 26 (53.1) 42 (44.2)
Wheezes/rhonchi 16 (34.8) 31 (63.3) 47 (49.5)
Diminished breath sounds 4 (8.7) 15 (30.6) 19 (20.0)
Crackles 10 (21.7) 18 (36.7) 28 (29.5)
Any abnormal chest finding 24 (52.2) 39 (79.6) 63 (66.3)
Admitted to hospital due to
exacerbation the year before
baseline
3 (6.6) 3 (6.1) 6 (6.4)
Exacerbation treated with
antibiotics the year before
baseline
13 (28.3) 24 (49.0) 37 (38.9)
Exacerbation treated with
systemic corticosteroids
the year before baseline
7 (15.2) 24 (49.0) 31 (32.6)
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also occur in patients with mild and well-controlled
asthma [17]. The assessment of the severity of an asthma
exacerbation is usually based on symptoms and physical
examination. Lung function and oxygen saturation may
also be measured [18]. Correction of hypoxemia, rapid
reversal of airway obstruction and reducing the risk of
relapse are the main targets for treatment of asthma
exacerbations [19]. Short-acting bronchodilators, oral
corticosteroids and oxygen, if the patient is hypoxemic,
are the main treatment options. Antibiotic therapy is not
recommended if the patient does not have pneumonia or
other bacterial infections at the same time [18].
More antibiotic prescribing than recommended in COPD
guidelines was found in a Dutch study from 2006 [20]. In a
cross-sectional study carried out in 6 countries in 2008,
Llor et al found that the antibiotic prescribing rate was
78.7% among patients with AECOPD, being higher in
patients with type 1 Anthonisen (94.2%), followed by type 2
(84.1%) and type 3 (65.8%). Even patients that did not have
any Anthonisen criteria received antibiotics (42.5%)
[21]. In all the Anthonisen groups, less antibiotics were
prescribed to patients tested with C-reactive protein
(CRP).
Due to the risk of microbial resistance development
[22] and the side effects of both antibiotics and systemic
corticosteroids [23,24], unnecessary use of these treat-
ments should be avoided.
In this study the patients with COPD or asthma exac-
erbations were, as a routine, tested with the following
three biomarkers: CRP test, spirometry and pulse oxim-
etry. We wanted to find out whether the GPs took the
results of these tests into account when prescribing anti-
biotics and systemic corticosteroids, and aimed at deter-
mining the predictive value of the biomarkers for such
prescribing, also when added to respiratory symptoms
and chest signs.
Methods
This is an observational multicenter prospective cohort
study with a baseline registration and a 12 months
follow-up period in primary care to investigate the pre-
dictors for treatment with antibiotics and systemic corti-
costeroids in patients with exacerbation of asthma or
COPD.
Setting and participants
Patients from seven general practice offices who were
40 years or older with a diagnosis of asthma or COPD
registered in their medical record the previous five years
were invited to a baseline study. Out of 380 patients
who met between April 2009 and March 2010, 376 were
deemed to be in a stable phase of their illness and per-
formed post-bronchodilator spirometry, 210 had beendiagnosed with asthma only and 166 with COPD (including
92 with both diagnosis) [3,7]. The GPs recorded whether or
not treatment with antibiotics and/or systemic corticoste-
roids had been prescribed for an exacerbation the previous
12 months, and the patients reported hospitalizations due
to exacerbations during the same period. Smoking status
and comorbidities were registered. All participants were
asked to contact their GP during exacerbations the
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registration have previously been reported [7].
The regional committee for Medical and Health Re-
search Ethics in North Norway approved the study. All
study participants gave written consent.
COPD exacerbation was defined as an increase in dys-
pnea, coughing or sputum amount that is acute in onset
and beyond normal day-to-day variations, which necessi-
tates a dosage adjustment of medication [12]. Asthma
exacerbations were defined as episodes of a progressive
increase in shortness of breath, cough, wheezing, or
chest tightness or a combination of these symptoms [19].
The patients were asked to consult their GPs within
2-3 days when they experience such an increase in
symptoms. For patients who visited the GP with sev-
eral exacerbations during follow up, the first exacer-
bation was, as a rule, included in the analysis. A later
exacerbation was chosen if the set of data from the
first exacerbation was not sufficiently complete.
When the patient consulted during an exacerbation,
the GPs registered and graded the patient’s symptoms,
chest findings, and the duration of the exacerbation and
whether the patient had taken antibiotics or systemic
corticosteroids the preceding days. Spirometry, CRP
and oxygen saturation were also measured during the
consultation.
Spirometry was performed according to the American
Thoracic Society/European Respiratory Society guidelines
[25], using a Spirare SPS310 Spirometer (Diagnostica AS,Figure 2 Percentages of 95 patients treated with antibiotics, systemic
before the consultaion.Oslo, Norway). The CRP rapid test was carried out using
Afinion AS100 Analyzer (Axis-Shield, Scotland), Orion
Quickread CRP (Orion Diagnostica Oy, Espoo, Finland),
or ABX Micros CRP (HORIBA medical, Montpellier,
France), oxygen saturation was measured by a digital
handheld pulse oximeter, Onyx II model 0550 (Nonin
Medical Inc., Plymouth, MN, USA).
Statistical analysis
The frequencies of prescribed treatment by patient’s
characteristics and clinical findings were analyzed separ-
ately in patients only diagnosed with asthma (the asthma
group) and in patients diagnosed with COPD or both
asthma and COPD (the COPD group). Patients, who
had started treatment with antibiotic or oral corticoste-
roids, respectively, before the consultation, were excluded
when predictors of prescribing antibiotic and corticoster-
oid treatment at the consultation were analyzed. When
comparing the prescribing between subgroups, Fisher’s
Exact Test was used for 2x2 tables and Chi square statis-
tics when continuous variables had been categorized into
more than two categories, usually examining linear-by-
linear association. Multivariable logistic regression was
done in the whole patient sample with antibiotic prescrib-
ing as outcome, adding CRP to relevant symptoms, signs
and COPD status at baseline in the explanatory model.
Likewise pulse oximetry results were added to symptoms,
signs and COPD status in a model with systemic cortico-
steroid prescribing as outcome. Goodness-of-fit was testedcorticosteroids or both, which includes the treatment taken
Table 2 Antibiotic prescribing by patient characteristics for exacerbations of asthma (41 patients) and COPD
(43 patients)
Asthma n (%) P-value COPD/Both n (%) P-value All n (%) P-value
All 6/41 (14.6) 15/43 (34.9) 21/84 (25.0)
Baseline characteristics
Age
≥65 years 1/13 (7.7) 0.4 9/25 (36.0) 0.6 10/38 (26.3) 0.5
<65 years 5/28 (17.9) 6/18 (33.3) 11/46 (23.9)
Gender
Male 3/15 (20.0) 0.4 5/16 (31.3) 0.5 8/31 (25.8) 0.5
Female 3/26 (11.5) 10/27 (37.0) 13/53 (24.5)
Smoking status
Never smoker 2/15 (13.3) 0.6* 2/8 (25.0) 0.7* 4/23 (17.4) 0.8*
Current smoker 3/11 (27.3) 8/16 (50.0) 11/27 (40.7)
Ex-smoker 1/15 (6.7) 5/19 (26.3) 6/34 (17.6)
Spirometry
FEV1/FVC <0.7 3/7 (42.9) 0.05 13/27 (48.1) 0.02 16/34 (47.1) < 0.001
Characteristics at exacerbation
Respiratory symptoms
Dyspnea, bothersome or very bothersome 6/38 (15.8) 0.6 15/41 (36.6) 0.4 21/79 (26.6) 0.2
very bothersome 2/9 (22.2) 0.4 6/15 (40.0) 0.4 8/24 (33.3) 0.2
Phlegm, bothersome or very bothersome 6/30 (20.0) 0.1 13/32(40.6) 0.2 19/62 (30.6) 0.04
very bothersome 2/7 (28.6) 0.3 4/6 (66.7) 0.09 6/13(46.2) 0.06
Purulence 4/19 (21.1) 0.3 6/18 (33.3) 0.5 10/37 (27.0) 0.4
Coughing, bothersome or very bothersome 6/38 (15.8) 0.6 14/38 (36.8) 0.4 20/76 (26.3) 0.3
very bothersome 2/14 (14.3) 0.7 6/12 (50.0) 0.2 8/26 (30.8) 0.3
Anthonisen criteria combined
Type III 0/10 (0) 0.08* 2/10 (20.0) 0.4* 2/20 (10.0) 0.1*
Type II 2/15 (13.3) 7/17 (41.2) 9/32 (28.1)
Type I 4/16 (25.0) 6/16 (37.5) 10/32 (31.3)
Chest findings Prolonged expiration 4/14 (28.6) 0.09 11/23 (47.8) 0.06 15/37 (40.5) 0.004
Wheezes/rhonchi 4/15 (26.7) 0.1 12/27 (44.4) 0.08 16/42 (38.1) 0.005
Diminished breath sounds 2/4 (50.0) 0.09 7/13 (53.8) 0.08 9/17 (52.9) 0.005
Crackles 2/9 (22.2) 0.4 7/16 (43.8) 0.3 9/25 (36.0) 0.1
Any abnormal chest finding 4/22 (18.2) 0.4 14/34 (41.2) 0.09 18/56 (32.1) 0.03
Lung functiona
FEV1% predicted < 50 0/1 (0) 0.9* 3/10 (30.0) 0.7* 3/11 (27.3) 0.2*
FEV1% predicted 50-80 2/10 (20.0) 10/25 (40.0) 12/35 (34.3)
FEV1% predicted≥ 80 4/25 (16.0) 1/6 (16.7) 5/31 (16.1)
C-reactive proteinb
<8 mg/L 4/24 (16.7) 0.9* 3/24 (12.5) <0.001* 7/48 (14.6) 0.001*
8-39 mg/L 2/11 (18.2) 6/10 (60.0) 8/21 (38.1)
≥40 mg/L 0/1 (0) 5/6 (83.3) 5/7 (71.4)
Oxygen saturation (SpO2)
c
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Table 2 Antibiotic prescribing by patient characteristics for exacerbations of asthma (41 patients) and COPD
(43 patients) (Continued)
>95% 5/27 (18.5) 0.3* 6/23 (26.1) 0.06* 11/50 (22.0) 0.01*
93-95% 0/3 (0) 1/8 (12.5) 1/11 (9.1)
<93% 1/1 (100) 6/9 (66.7) 7/10 (70.0)
*P-value calculated using linear-by-linear Chi-Square tests otherwise P-value calculated using Fisher’s Exact Test.
a7 missing, 5 in asthma group and 2 in the COPD/Both group.
b8 missing, 5 in asthma group and 3 in the COPD/Both group.
c13 missing, 10 in asthma group and 3 in the COPD/Both group.
Table 3 Predictors for treatment with antibiotics during
exacerbations in 84 patients with asthma or COPD using
multivariable logistic regression
OR (95%CI) P-value
FEV1/FVC < 0.7 - yes vs no 4.6 (1.3-17.1) 0.02
Bothersome or very bothersome phlegm 3.1 (0.5-18.3) 0.2
Prolonged expiration 2.2 (0.6-8.4) 0.2
C-reactive protein≥ 8 mg/L - pos vs neg 4.3 (1.3-14.8) 0.02
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was performed using the SPSS version 19 (IBM, Armonk,
NY, USA).
Results
During the one-year follow-up period, 109 patients vis-
ited their GP due to one or more exacerbations. Of
these, 14 patients were excluded due to incomplete data,
and 95 patients were included in the analysis (Figure 1),
63.2% were female and 47.4% were 65 years or older
(mean age 62.1 years). Based on the diagnosis made by
the GPs, 46 patients (48.4%) were only registered with
asthma, and 49 patients (51.6%) with COPD (or both
diagnoses). FEV1/FVC < 0.7 post-bronchodilator had been
found at baseline in 39 of the patients (41.1%, mean age
65.2 years); whereas 56 patients (58.9%) had FEV1/FVC ≥
0.7 (mean age 59.9 years). Other baseline characteristics
are shown in Table 1.
During exacerbation, bothersome or very bothersome
dyspnea was the most frequent symptom recorded by
the GPs in the whole sample of patients whether diag-
nosed with asthma or not, followed by coughing and
phlegm (Table 1). Purulence was recorded in 42.9% in
the COPD group and in 50% in the asthma group. Of
the chest findings, wheezes and prolonged expiration
were most frequently registered. When adding medica-
tion taken prior to the consultation, 8.4% of the included
patients were treated with antibiotics alone, 22.1% were
treated with systemic corticosteroids alone, and 25.3%
were treated with both medications (Figure 2). Patients
in the COPD group were treated more often with antibi-
otics and systemic corticosteroids than those in the
asthma group (Figure 2).
Predictors of antibiotic prescribing
Antibiotic prescribing in the whole sample of patients in-
creased with increasing symptom load from 10% in patients
with Anthonisen type III, to 28.1% in type II and 31.3% in
patients with type I (P = 0.1, Table 2). This association was
still not statistically significant when the analysis was done
separately in the asthma and COPD groups. Among COPD
patients with purulence, 33.3% were prescribed antibiotics
(P = 0.5), whereas the corresponding figure in COPD pa-
tients with bothersome or very bothersome phlegm was40.6% (P = 0.2), and phlegm was a significant predictor of
antibiotic prescribing in the whole sample (P = 0.04). All
the chest findings except crackles were significant predic-
tors of antibiotic prescribing in the whole sample of
patients (Table 2). The prescribing rate increased with
increasing CRP value in the COPD group and in the
whole sample of patients as shown in (Table 2). The
same trend was found regarding oxygen saturation,
with increased prescribing rate in patients with oxygen
saturation less than 93%. The strong association be-
tween antibiotic prescribing and both baseline FEV1/
FVC < 0.7 and raised CRP values were confirmed by
the multivariable analysis (Table 3). The P-value of the
Hosmer and Lemeshow goodness-of-fit test was 0.6.
Predictors of prescribing systemic corticosteroids
Being 65 years old or more was a significant predictor of
prescribing systemic corticosteroids only in patients with
asthma, P = 0.03 (Table 4). Of the symptoms recorded by
GPs, very bothersome dyspnea and coughing predicted
the treatment with systemic corticosteroids in patients
in the COPD group, but not in the asthma group.
Crackles were the only chest finding predicting treat-
ment with systemic corticosteroids in the COPD group
(P = 0.003), while prolonged expiration and diminished
breath sounds were significant in predicting this type of
treatment in patients with asthma (Table 4). All the pa-
tients with C-reactive protein (CRP) ≥ 40 were treated
with systemic corticosteroids regardless diagnosis, and
the prescribing rate increased with decreasing oxygen
saturation in the COPD group (P = 0.004).
By entering FEV1/FVC < 0.7 at baseline, very bother-
some dyspnea, crackles and pulse oximetry ≤ 92% into
multivariate logistic regression model (Table 5), FEV1/
Table 4 Systemic corticosteroid prescribing by patient characteristics for exacerbations of asthma (39 patients) and
COPD (40 patients)
Asthma n (%) P-value COPD/Both n (%) P-value All n (%) P-value
All 12/39 (30.8) 17/40 (42.5) 29/79 (36.7)
Baseline characteristics
Age
≥65 years 1/13 (7.7) 0.03 10/23 (43.5) 0.5 11/36 (30.6) 0.2
<65 years 11/26 (42.3) 7/17 (41.2) 18/43 (41.9)
Gender
Male 3/13 (23.1) 0.4 8/13 (61.5) 0.09 11/26 (42.3) 0.3
Female 9/26 (34.6) 9/27 (33.3) 18/53 (34.0)
Smoking status
Never smoker 3/16 (18.8) 0.5* 0/7 (0) 0.2* 3/23 (13.0) 0.1*
Current smoker 5/9 (55.6) 10/17 (58.8) 15/26 (57.7)
Ex-smoker 4/14 (28.6) 7/16 (43.8) 11/30 (36.7)
Spirometry
FEV1/FVC < 0.7 3/5 (60.0) 0.1 15/25 (60.0) 0.004 18/30 (60.0) 0.001
Characteristics at exacerbation
Respiratory symptoms
Dyspnea, bothersome or very bothersome 11/35 (31.4) 0.6 17/38 (44.7) 0.3 28/73 (38.4) 0.3
very bothersome 4/9 (44.4) 0.3 9/12 (75.0) 0.01 13/21 (61.9) 0.006
Phlegm, bothersome or very bothersome 10/28 (35.7) 0.2 14/31 (45.2) 0.4 24/59 (40.7) 0.2
very bothersome 2/7 (28.6) 0.6 5/7 (71.4) 0.1 7/14 (50.0) 0.2
Purulence 7/17 (41.2) 0.2 7/18 (38.9) 0.2 14/35 (40.0) 0.4
Coughing, bothersome or very bothersome 12/35 (34.3) 0.2 17/36 (47.2) 0.09 29/71 (40.8) 0.02
Very bothersome 5/14 (35.7) 0.4 9/13 (69.2) 0.02 14/27 (51.9) 0.04
Anthonisen criteria combined
Type III 2/11 (18.2) 0.08* 3/8 (37.5) 0.8* 5/19 (26.3) 0.1*
Type II 3/14 (21.4) 7/16 (43.8) 10/30 (33.3)
Type I 7/14 (50.0) 7/16 (43.8) 14/30 (46.7)
Chest findings
Prolonged expiration 7/13 (53.8) 0.03 12/23 (52.2) 0.1 19/36 (52.8) 0.006
Wheezes/rhonchi 7/14 (50.0) 0.06 13/26 (50.0) 0.2 20/40 (50.0) 0.01
Diminished breath sounds 4/4 (100) 0.006 7/12 (58.3) 0.2 11/16 (68.8) 0.004
Crackles 4/8 (50.0) 0.2 12/17 (70.6) 0.003 16/25 (64.0) 0.001
Any abnormal chest finding 9/21 (42.9) 0.08 15/33 (45.5) 0.3 24/54 (44.4) 0.03
Lung functiona
FEV1% predicted < 50 0/1 (0) 0.8* 5/10 (50.0) 0.08* 5/11 (45.5) 0.1*
FEV1% predicted 50-80 4/9 (44.4) 10/22 (45.5) 14/31 (45.2)
FEV1% predicted≥ 80 7/23 (30.4) 0/6 (0) 7/29 (24.1)
C-reactive proteinb
<8 mg/L 7/21 (33.3) 0.4* 7/21 (33.3) 0.02* 14/42 (33.3) 0.01*
8-39 mg/L 4/11 (36.4) 3/10 (30.0) 7/21 (33.3)
≥40 mg/L 1/1 (100) 6/6 (100) 7/7 (100)
Oxygen saturation (SpO2)
c
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Table 4 Systemic corticosteroid prescribing by patient characteristics for exacerbations of asthma (39 patients) and
COPD (40 patients) (Continued)
>95% 8/24 (33.3) 0.3* 6/23 (26.1) 0.004* 14/47 (29.8) 0.003*
93-95% 1/3 (33.3) 2/6 (33.3) 3/9 (33.3)
<93% 1/1 (100) 7/8 (87.5) 8/9 (88.9)
*P-value calculated using linear-by-linear Chi-Square tests otherwise P-value calculated using Fisher’s Exact Test.
a8 missing, 6 in asthma group and 2 in the COPD/Both group.
b9 missing, 6 in asthma group and 3 in the COPD/Both group.
c14 missing, 11 in asthma group and 3 in the COPD/Both group.
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dictors of prescribing. The P-value of the Hosmer and
Lemeshow goodness-of-fit test was 0.47.
Discussion
Main findings
Patients diagnosed with COPD or both COPD and
asthma by theirs GPs at baseline, were treated more
often with antibiotics and systemic corticosteroids during
exacerbations than the patients only diagnosed with
asthma. Most remarkably we found that the presence
of purulence did not significantly predict antibiotic
prescribing, not even among the COPD patients, whereas
chest finding and biomarkers were significant predictors
of the prescribing of both antibiotics and corticosteroids.
Comparisons with other studies
In our study increased phlegm was the only Anthonisen
criterion significantly associated with antibiotic prescribing.
In an international study on antibiotic treatment of COPD
exacerbation by Llor et al., purulence was the strongest
predictor of antibiotics prescribing in countries without
access to CRP testing [21]. Where the CRP test was
available purulence was still a strong predictor of anti-
biotic prescribing, but in contrast to our study, CRP
testing was not carried out as a routine in all patients.
In a British study of patients with lower respiratory
tract infection, including patients with AECOPD, anti-
biotic prescribing was associated with both purulence
and abnormal chest findings [26]. Strong emphasis laid
on chest findings when prescribing antibiotics has also
been reported in other previous studies [27-29].
Llor et al. found that the availability (and use) of CRP
testing reduced the weight laid on the presence ofTable 5 Predictors for treatment with systemic
corticosteroids during exacerbations in 79 patients with
asthma or COPD using multivariable logistic regression
OR (95%CI) P-value
FEV1/FVC < 0.7 - yes vs no 3.7 (1.1-11.7) 0.03
Very bothersome dyspnea - yes vs no 2.9 (0.8-9.9) 0.09
Crackles - yes vs no 4.3 (1.3-14.0) 0.01
Oxygen saturation (SpO2) < 93% - yes vs no 5.7 (0.6-56.4) 0.1purulence [21], similar to that found in a study on pa-
tients with acute cough [28]. The use of the CRP in
AECOPD was strongly supported in a recent study. A
CRP value > 40 mg/L was the strongest predictor of
treatment failure in the placebo arm of a clinical trial
with AECOPD patients [13]. In Norway, the antibiotic
prescribing rate for lower respiratory tract infection is
lower than in most European countries [30]. One explan-
ation may be easy access to CRP testing, which has shown
to influence the prescribing rate by reducing the unneces-
sary prescription of antibiotics in patients presenting with
acute cough in primary care [31].
Systemic corticosteroids were more frequently pre-
scribed than antibiotics. Although prescribing systemic
corticosteroids in the management of exacerbations of
COPD or asthma seems to be less controversial than the
prescription of antibiotics [12,19], antibiotics have been
shown to be the more frequently prescribed of these two
medications in a study from Sweden [32]. A greater pro-
portion of our patients had also been treated with antibi-
otics than with systemic corticosteroids the year prior to
the baseline examination. The systematic information
from pulse oximetry and CRP test might have contrib-
uted to a twist in the treatment in favor of systemic
corticosteroids.
Treating asthma exacerbations with systemic corticoste-
roids is recommended in the current guidelines when
short-acting beta 2-agonists do not give sufficient relief
[18]. Among the patients only diagnosed with asthma by
their GPs, prolonged expiration and diminished breath
sounds were the strongest predictors, although not on the
list of signs indicating severe asthma attacks in the guide-
lines from Global Initiative for Asthma (GINA) [18,19].
Strengths and limitations
As far as we know, this is the first observational study in
primary care to investigate the predictors for treatment
with antibiotics and systemic corticosteroids including
patients with asthma, COPD or both in one patient sam-
ple. However, limitations in this study necessitate some
caution when interpreting the results. The small number
of patients included in the analysis made the results less
reliable in particular after dividing the patients into
asthma and COPD groups. CRP values ≥ 40 mg/L and
Al-ani et al. BMC Family Practice  (2015) 16:40 Page 9 of 10SpO2 values ≤ 92 were strongly associated with high pre-
scribing rates of both antibiotics and systemic corticoste-
roids, and the predictive value of other findings may
have been influenced by the co-presence of such find-
ings. For instance, the finding of crackles was signifi-
cantly associated with low oxygen saturation (P = 0.001),
and this might have contributed to the high prescribing
rate of systemic corticosteroids in the patients with crackles.
However, crackles was still a significant predictor of systemic
corticosteroid prescribing in the multivariable analysis.
This study does not show what is really going on in
daily practice, but what may happen with decisions on
prescribing when both CRP testing and pulse oximetry
is carried out as a routine. Even when these tests are
available they would not have been applied in the same
way by the GPs in a real life situation. Pulse oximetry
has so far not been frequently used in the assessment of
exacerbations, although recommended in both the GOLD
(Global Initiative for Chronic Obstructive Lung Disease)
and GINA guidelines. In other settings, external factors
such as short consultation times and the patient’s social
circumstances influence prescribing behavior [33].
The inclusion of both asthma and COPD patients may
be regarded as a weakness of the study. On the other
hand, this mix of patients reflects real life in primary
care, where it is often difficult to decide which of the
two diseases the patient suffers from. FEV1/FVC ≥ 0.7
had been found in some patients in the COPD group at
baseline, and FEV1/FVC < 0.7 in some patients in asthma
group. Some symptoms typical for COPD were regis-
tered with almost similar frequency in both groups, such
as increased phlegm and purulence. This indicates that
the classification of patients into COPD and non-COPD
groups is not crystal clear and that some patients with
FEV1/FVC ≥ 0.7 suffered from an early COPD. In the
COPD group more than half of the patients had also
been given an asthma diagnosis the previous 5 years.
COPD was most frequently the last diagnosis of the two
[3], and there had been a trend of change in diagnosis
from asthma to COPD since 1995 [34]. Asthma can de-
velop into COPD [35], and a tendency to choose an
asthma diagnosis when COPD could be questioned was
strengthened by the reimbursement regulations for re-
spiratory medication introduced in Norway in 2006.
When the study was carried out, costs of inhaled corti-
costeroids combined with long-acting β2-agonists could
be reimbursed, as a rule, only in patients with a diagno-
sis of asthma.
Implications of the study
The GPs relied on the findings by physical examination,
CRP and pulse oximetry more than on the patient’s respira-
tory symptoms when deciding type of treatment. While the
usefulness of CRP is already strongly supported by recentevidence, the role of chest findings and oxygen saturation is
not yet clear. Since GPs seems to heavily rely on chest find-
ings in their treatment decisions, it will be interesting to
evaluate their usefulness as clues for treatment for asthma
and COPD in future studies. With more evidence available,
it might be possible to decide whether or not the applica-
tion of chest findings, CRP testing and pulse oximetry can
lead to improved patient outcomes related to COPD and/
or asthma exacerbations.
Conclusion
In this study where CRP testing and pulse oximetry were
carried out as routine, chest findings, together with the
results of CRP and oxygen saturation were stronger pre-
dictors in choosing the type of treatment in patients suf-
fering from exacerbation of asthma or COPD than were
respiratory symptoms.
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